Literature DB >> 2758029

Further studies on the mechanism of inhibition of intestinal chylomicron transport by Pluronic L-81.

D Nutting1, J Hall, J A Barrowman, P Tso.   

Abstract

This study explored further the hypothesis that intestinal cells have two pathways for producing large triacylglycerol-rich lipoprotein particles. The hydrophobic surfactant Pluronic L-81 (L-81) inhibits formation of chylomicrons (containing triacylglycerol synthesized from dietary fatty acids and monoacylglycerol, through the monoacylglycerol pathway), but not formation of very-low-density lipoproteins. L-81 does not inhibit lymphatic lipid transport during infusion of egg phosphatidylcholine, whose fatty acid is processed through the alpha-glycerol phosphate pathway and is transported in lymph in very-low-density lipoproteins. Thus, the first part of this study tested whether L-81 cannot inhibit the alpha-glycerol phosphate pathway, and thus L-81 can only affect chylomicron lipid secretion. Intestinal lymph fistula rats were infused with a lipid emulsion containing [1-14C]oleic acid, but no monoacylglycerol, to ensure that the oleic acid will be channeled to the alpha-glycerol phosphate pathway. Experimental rats received 1 mg/h of L-81 in their emulsion whereas control rats lacked L-81. Lymphatic triacylglycerol output, measured both chemically and radioactively, was markedly suppressed in the experimental rats as compared to the controls. Thus, these data indicate that the reason why lipid transport was unaffected by L-81 when egg phosphatidylcholine was infused was not because of the pathway used for the resynthesis of triacylglycerol from phosphatidylcholine. In the second part of this study, we measured the appearance time for chylomicron (in control rats) and for very-low-density lipoprotein (in L-81-treated rats). The appearance time is defined as the time between placement of radioactive fatty acid into the intestinal lumen and the appearance of radioactive lipid in the central lacteal. The average appearance time for the control rats was 10.8 min, which was significantly shorter than the 16.2 min in the L-81-treated experimental rats. This difference in appearance time further supports the hypothesis that chylomicron and very-low-density lipoprotein are packaged separately in the enterocytes and only the formation of chylomicron is inhibited by L-81.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2758029     DOI: 10.1016/0005-2760(89)90084-2

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Relationship of phosphatidylcholine to hydrophobic surfactant on rat intestinal chylomicron secretion.

Authors:  J B Rodgers; D A Beeler; P Tso
Journal:  Experientia       Date:  1996-07-15

2.  Modulation of immune cell proliferation by glycerol monolaurate.

Authors:  K J Witcher; R P Novick; P M Schlievert
Journal:  Clin Diagn Lab Immunol       Date:  1996-01

3.  Chylomicron formation and secretion is required for lipid-stimulated release of incretins GLP-1 and GIP.

Authors:  Wendell J Lu; Qing Yang; Li Yang; Dana Lee; David D'Alessio; Patrick Tso
Journal:  Lipids       Date:  2012-06       Impact factor: 1.880

4.  Visualization of lipid metabolism in the zebrafish intestine reveals a relationship between NPC1L1-mediated cholesterol uptake and dietary fatty acid.

Authors:  James W Walters; Jennifer L Anderson; Robert Bittman; Michael Pack; Steven A Farber
Journal:  Chem Biol       Date:  2012-06-28

5.  Effect of pluronic L-81 on intestinal lipoprotein secretion in the rat.

Authors:  J Pidlich; F Renner; A Ellinger; M Hüttinger; M Pavelka; A Gangl
Journal:  Dig Dis Sci       Date:  1996-07       Impact factor: 3.199

6.  A possible role for rat intestinal surfactant-like particles in transepithelial triacylglycerol transport.

Authors:  A Mahmood; F Yamagishi; R Eliakim; K DeSchryver-Kecskemeti; T L Gramlich; D H Alpers
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

Review 7.  Intestinal lymphatic transport for drug delivery.

Authors:  Jaime A Yáñez; Stephen W J Wang; Ian W Knemeyer; Mark A Wirth; Kevin B Alton
Journal:  Adv Drug Deliv Rev       Date:  2011-06-13       Impact factor: 15.470

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.